Evidence map›Paper›PMID 41256965›Full record

ArticleJTO clinical and research reports2025

Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes.

Surbhi Singhal, Caressa Hui, Joel W Neal, Seema Nagpal, Mohana Roy, Millie Das, Kavitha Ramchandran, Erqi Pollom, Giovanni Selvaggi, Heather A Wakelee and 1 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Surbhi SinghalDivision of Hematology/Oncology, Department of Medicine, University of California Davis, Sacramento, California.
Caressa HuiDepartment of Radiation Oncology, University of California Irvine, Irvine, California.
Joel W NealDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, California.
Seema NagpalDepartment of Neurology, Stanford University, Stanford, California.
Mohana RoyDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, California.
Millie DasDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, California.
Kavitha RamchandranDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, California.
Erqi PollomDepartment of Radiation Oncology, Stanford University, Stanford, California.
Giovanni SelvaggiXcovery Holdings Inc., Miami, Florida.
Heather A WakeleeDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, California.
Nathaniel J MyallDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, California.

Funding

UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development ProgramK12CA138464 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BIRKELAND, ANDREW CHARLES, LARA, PRIMO N. · 2011 to 2025
$11.4M
NCI NIH HHS K12 CA138464
6 · The paper itself

Abstract

Introduction: Central nervous system (CNS) metastases are common in Methods: This retrospective study included patients who developed CNS progression (time 0, [T0]) on alectinib, lorlatinib, brigatinib, or ensartinib. Patients were characterized according to TKI management (i.e., TKI unaltered, TKI-altered [switched TKI or increased TKI dose], TKI discontinued) at T0. Intracranial progression-free survival was evaluated using Kaplan-Meier and compared using the log-rank test. Results: Among 98 patients treated with a CNS-penetrable TKI, 36 (37%) experienced CNS progression. Overall, 33 (92%) developed parenchymal and seven (19%) developed leptomeningeal progression, respectively. At T0, 16 (44%) had TKI unaltered, 14 (39%) had TKI altered (eight switched TKI, six increased TKI dose), and six (17%) discontinued TKI. Patients with TKI-altered tended to have more frequent leptomeningeal disease or concurrent systemic progression at T0. Intracranial radiation was given at T0 in 14 (88%) of TKI-unaltered and three (21%) of TKI-altered patients. The median intracranial progression-free survival from T0 was not significantly different between the TKI-altered versus unaltered groups ( Conclusions: For patients with

Indexed as

ALK-rearranged NSCLCCentral nervous system progressionIntracranial metastasesLeptomeningeal diseaseTargeted therapy

Identifiers

PMID41256965
PMCPMC12621429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.